搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
News Medical on MSN
7 小时
Novel multi-biomarker approach enhances chronic kidney disease risk assessment
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically ...
PipelineReview.com
3 小时
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy ...
CAMBRIDGE, MA, USA I6, 2024 I Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an ...
News Medical on MSN
7 小时
New trial shows felzartamab reduces proteinuria in IgA nephropathy patients
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.
Medpage Today on MSN
12 小时
Alternative Pathway Inhibition Makes Good in IgA Nephropathy
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈